Sitryx initiates Phase 1 clinical trial of potential disease-modifying treatment for atopic dermatitis SYX-5219 SYX-5219 is a ...

Previously reported Phase 1/2 data on WU-CART-007 demonstrated clinically manageable safety and evidence of anti-leukemic activity with an overall response rate of 91% and composite complete remission ...

Adolescents with SCD often struggle with maintaining friendships, school performance, and participation in extracurricular ...

For the first time, scientists have systematically analyzed somatic mutations in stomach lining tissue to unpick mutational ...

Century Therapeutics has joined the onslaught of cell therapy biotechs taking hits, discontinuing a phase 1 cancer study to ...

Stomach cancer, also known as gastric cancer, is the fifth most common cancer worldwide, with nearly one million new cases in ...

Innovent and HUTCHMED received conditional approval for the combo in endometrial cancer from China’s NMPA last year.

There is a trial of strength at the cellular level. Cells are in constant competition with each other and so eliminate ...

As AstraZeneca awaits an FDA decision for its Daiichi Sankyo-partnered Datroway in EGFR-mutated non-small cell lung cancer ...

India's gene therapy for blood cancers shows 73% response rate, offering hope and cost-effective treatment for patients.

Thanks to the scientific efforts of a team led by Professor Suzannah Williams of Oxford University, researchers are looking ...

DWTX READ THE FULL DWTX RESEARCH REPORT Business Update First Patient Dosed in Phase 2b Trial of Halneuron® On March 18, 2025 ...